A troubling disconnect between medical expertise and insurance mandates is putting patients' health at risk. Policies like step therapy and prior authorization are forcing individuals into treatments not recommended by their doctors—often with devastating consequences. In this episode, we hear from a patient who endured months of suffering due to her insurer's 'fail-first' requirements. We also talk with a doctor navigating this impossible system and a biotech leader fighting to ensure innovative treatments reach the patients who need them most. 

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins.

In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

There are over 7000 rare diseases identified in the U.S. alone. Many of these diseases affect children, leaving families desperate for answers. In this episode, we talk with one of those families and the biotech company offering them new hope. We also talk with an expert on policy that has jump-started R&D for rare diseases.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

As the global population approaches 10 billion by 2050, the challenge of providing safe, nutritious food is growing more urgent. Climate change is further straining food systems, impacting water availability, crop yields, and livestock health. In this episode, two experts discuss innovative biotech solutions aimed at addressing these pressing issues, offering hope for a sustainable path forward in feeding the world.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

Since Watson and Crick discovered DNA's double helix structure in 1953, the US has been a leader in biotechnology innovation. American excellence in this field has greatly benefited people around the world. In this episode, we talk about why this leadership position may be threatened and why that matters to our national security.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

David Fajgenbaum was in his third year of medical school when he was diagnosed with a rare and life-threatening disease that began shutting down his organs, bringing him perilously close to death. Although he survived the initial episode, he faced four additional relapses, each pushing him to the brink of death. In this episode, we speak with David about his relentless journey to discover the treatment that ultimately put his disease into remission. We also explore how his personal battle inspired the creation of a groundbreaking approach to help others suffering from rare diseases.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits.

2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. 

YOU asked, and we answered. In this episode, we had our experts on standby to answer questions from you, our listeners. We discuss topics ranging from the safety of genetically modified foods (GMOs), to the new era of personalized medicine, feeding the world by 2050, and even what makes start-up companies attractive to investors.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body.  We discuss the progress and the challenge in making this breakthrough a reality. 

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/